The involvement of aldose reductase in diabetic compli

Diabetes/metabolism Reviews

4, 323-337

DOI: 10.1002/dmr.5610040403

Citation Report

#	Article	IF	Citations
1	Isolation and characterization of cDNA clones encoding aldose reductase. Current Eye Research, 1989, 8, 1021-1027.	0.7	28
2	The contributions of Jin H. Kinoshita to aldose reductase research. Experimental Eye Research, 1990, 50, 615-620.	1.2	7
3	The role of lens epithelium in sugar cataract formation. Experimental Eye Research, 1990, 50, 641-646.	1.2	58
4	Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Experimental Eye Research, 1990, 50, 355-366.	1.2	70
5	Monoaminoguanidine inhibits aldose reductase. Biochemical Pharmacology, 1991, 41, 1527-1528.	2.0	19
6	Purification, crystallization and preliminary crystallographic analysis of porcine aldose reductase. Journal of Molecular Biology, 1991, 218, 695-698.	2.0	12
7	Strategies in diabetes mellitus. Postgraduate Medicine, 1991, 89, 45-63.	0.9	5
8	Degenerated intramural pericytes (â€˜ghost cellsâ€™) in the retinal capillaries of diabetic rats. Current Eye Research, 1991, 10, 339-350.	0.7	72
9	Effects of diabetes on cholinergic transmission in two rat gut preparations. Gastroenterology, 1991, 100, 123-128.	0.6	34
10	Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats. Pharmaceutical Research, 1991, 08, 1511-1515.	1.7	18
11	Glucoseâ€induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes/metabolism Reviews, 1991, 7, 35-59.	0.2	137
12	Resolving isoforms of aldose reductase by preparative isoelectric focusing in the Rotofor. Electrophoresis, 1991, 12, 84-90.	1.3	23
13	Monoaminoguanidine prevents sorbitol accumulation, nonenzymatic protein glycosylation and development of kidney lesions in diabetic rats. Experientia, 1991, 47, 252-254.	1.2	11
14	Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. Diabetologia, 1991, 34, 695-701.	2.9	48
15	Adverse Drug Effects: Part II. Annals of Pharmacotherapy, 1992, 26, 550-554.	0.9	2
17	Aldose reductase mRNA expression and its activity are induced by glucose in fetal rat aortic smooth muscle (A10) cells. Life Sciences, 1992, 51, 719-726.	2.0	19
18	Site-directed mutagenesis of His-42, His-188 and Lys-263 of human aldose reductase. Biochemical and Biophysical Research Communications, 1992, 183, 327-333.	1.0	21
19	Does sorbinil bind to the substrate binding site of aldose reductase?. Biochemical Pharmacology, 1992, 44, 2427-2429.	2.0	23

#	Article	IF	Citations
20	Glucose and diabetic vascular disease 1. FASEB Journal, 1992, 6, 2905-2914.	0.2	361
21	Changes in Aldose Reductase After Crush Injury of Normal Rat Sciatic Nerve. Journal of Neurochemistry, 1992, 58, 2212-2220.	2.1	11
22	Aldose reductase: Congenial and injurious profiles of an enigmatic enzyme. Biochemical Medicine and Metabolic Biology, 1992, 48, 91-121.	0.7	143
23	Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. The Histochemical Journal, 1993, 25, 648-663.	0.6	47
24	EFFECTS OF ALDOSE REDUCTASE INHIBITION WITH EPALRESTAT ON DIABETES-INDUCED CHANGES IN RAT ISOLATED ATRIA. Clinical and Experimental Pharmacology and Physiology, 1993, 20, 207-213.	0.9	8
25	Sorbitol dehydrogenase. Full-length cDNA sequencing reveals a mRNA coding for a protein containing an additional 42 amino acids at the N-terminal end. FEBS Journal, 1993, 217, 83-87.	0.2	9
26	Crystallization and preliminary structure determination of porcine aldehyde reductase from two crystal forms. Acta Crystallographica Section D: Biological Crystallography, 1993, 49, 490-496.	2.5	5
27	Aldose and aldehyde reductases from human kidney cortex and medulla. BBA - Proteins and Proteomics, 1993, 1203, 260-266.	2.1	16
28	Diabetic rats show more resistance to neuromuscular blockade induced by aminoglycoside antibiotics. General Pharmacology, 1993, 24, 1415-1418.	0.7	3
29	Quantitative determination of human aldose reductase by enzyme-linked immunosorbent assay. Biochemical Pharmacology, 1993, 46, 21-28.	2.0	38
30	Molecular cloning of testicular 20.alpha.-hydroxysteroid dehydrogenase: Identity with aldose reductase. Biochemistry, 1993, 32, 1401-1406.	1.2	92
31	Hyperglycemic Pseudohypoxia and Diabetic Complications. Diabetes, 1993, 42, 801-813.	0.3	780
32	Levels of expression of hexokinase, aldose reductase and sorbitol dehydrogenase genes in lens of mouse and rat. Current Eye Research, 1993, 12, 323-332.	0.7	15
33	Aldose Reductase Inhibitors: An Update. Annals of Pharmacotherapy, 1993, 27, 751-754.	0.9	40
34	Enzyme immunoassay for erythrocyte aldose reductase. Clinical Chemistry, 1994, 40, 889-894.	1.5	29
35	High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia, 1994, 37, 328-330.	2.9	62
36	Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Documenta Ophthalmologica, 1994, 87, 355-365.	1.0	24
37	Diabetic nephropathy, renal hemodynamics, and aldose reductase inhibitors. Drug Development Research, 1994, 32, 104-116.	1.4	8

#	Article	IF	Citations
38	Structures of human and porcine aldehyde reductase: an enzyme implicated in diabetic complications. Acta Crystallographica Section D: Biological Crystallography, 1994, 50, 859-868.	2.5	32
39	Polyol and water accumulation in muscle of galactose-fed rats. Biochemical Pharmacology, 1994, 48, 1839-1841.	2.0	2
40	Pharmacokinetics of the Aldose Reductase Inhibitor, Zopolrestat, in Humans. Journal of Clinical Pharmacology, 1994, 34, 760-766.	1.0	18
41	Crystallization and preliminary structure of porcine aldehyde reductaseâ€"NADPH binary complex. Acta Crystallographica Section D: Biological Crystallography, 1995, 51, 605-608.	2.5	1
42	Presence of a Closely Related Subgroup in the Aldo-ketoreductase Family of the Mouse. FEBS Journal, 1995, 227, 448-453.	0.2	53
43	The role of polyols in the pathophysiology of hypergalactosemia. European Journal of Pediatrics, 1995, 154, S53-S64.	1.3	61
44	Structure of porcine aldehyde reductase holoenzyme. Nature Structural Biology, 1995, 2, 687-692.	9.7	54
45	The role of aldose reductase in diabetic retinopathy: Prevention and intervention studies. Progress in Retinal and Eye Research, 1995, 14, 593-640.	7.3	17
46	Residues affecting the catalysis and inhibition of rat lens aldose reductase. BBA - Proteins and Proteomics, 1995, 1246, 67-73.	2.1	23
47	Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. BBA - Proteins and Proteomics, 1995, 1249, 117-126.	2.1	163
48	Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes/metabolism Reviews, 1995, 11, 193-225.	0.2	147
49	Acridine orange differential staining of total DNA and RNA in normal and galactosemic lens epithelial cells in culture using flow cytometry. Current Eye Research, 1995, 14, 269-273.	0.7	14
50	Isolation of aldose reductase inhibitors from the flowers ofChrysanthemum boreale. Archives of Pharmacal Research, 1995, 18, 65-68.	2.7	42
51	New approaches for treatment in diabetes: Aldose reductase inhibitors. Biomedicine and Pharmacotherapy, 1995, 49, 232-243.	2.5	55
52	Calcium-mediated disintegrative globulization of isolated ocular lens fibers mimics cataractogenesis. Experimental Eye Research, 1995, 61, 303-310.	1.2	24
53	Characterization of the promoter of the gene for a mouse vas deferens protein related to the aldo-keto reductase superfamily: Effect of steroid hormones and phorbol esters. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 315-325.	1.2	8
54	THE CELLULAR AND MOLECULAR MECHANISMS OF DIABETIC COMPLICATIONS. Endocrinology and Metabolism Clinics of North America, 1996, 25, 255-270.	1.2	251
55	Kinetic and Spectroscopic Evidence for Active Site Inhibition of Human Aldose Reductaseâ€,â€¡. Biochemistry, 1996, 35, 11196-11202.	1.2	39

#	Article	IF	Citations
56	Synthesis and Aldose Reductase-Inhibitory Activity of Imidazopyrroloquinoline Esters.. Chemical and Pharmaceutical Bulletin, 1996, 44, 1493-1497.	0.6	8
57	Chromosome 7q35 and susceptibility to diabetic microvascular complications. Journal of Diabetes and Its Complications, 1996, 10, 62-67.	1.2	24
58	Hormonal Regulation of Aldose Reductase in Rat Ovary During the Estrous Cycle. FEBS Journal, 1996, 235, 444-448.	0.2	18
59	Crystallization and preliminary X-ray diffraction study of aldehyde reductase from a red yeast, Sporobolomyces salmonicolor. Acta Crystallographica Section D: Biological Crystallography, 1996, 52, 405-406.	2.5	4
60	Cloning, Expression, and Chaperone-like Activity of Human Î±A-Crystallin. Journal of Biological Chemistry, 1996, 271, 31973-31980.	1.6	158
61	Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 488-492.	1.8	60
62	Microvasculature in diabetes. Cardiovascular Research, 1996, 32, 764-771.	1.8	30
63	Isolation of the Mouse Aldose Reductase Promoter and Identification of a Tonicity-responsive Element. Journal of Biological Chemistry, 1997, 272, 2615-2619.	1.6	36
64	NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast Candida tenuis: Isolation, characterization and biochemical properties of the enzyme. Biochemical Journal, 1997, 326, 683-692.	1.7	105
65	Inhibition of Aldose Reductase and Sorbitol Accumulation by Astilbin and Taxifolin Dihydroflavonols inEngelhardtia chrysolepis. Bioscience, Biotechnology and Biochemistry, 1997, 61, 651-654.	0.6	58
66	Polyol pathway activation and glutathione redox status in nonâ€"insulin-dependent diabetic patients. Metabolism: Clinical and Experimental, 1997, 46, 1194-1198.	1.5	77
67	Sensitive, selective gas chromatographicâ€"mass spectrometric analysis with trifluoroacetyl derivatives and a stable isotope for studying tissue sorbitol-producing activity. Biomedical Applications, 1997, 688, 1-10.	1.7	5
68	Studies on the inhibitor-binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme-inhibitor ternary complex. , 1997, 29, 186-192.		30
69	Clinical analysis of aldose reductase for differential diagnosis of the pathogenesis of diabetic complication. Analytica Chimica Acta, 1998, 365, 285-292.	2.6	22
70	Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis. FEBS Journal, 1998, 256, 310-316.	0.2	20
71	Decreases in Raf-1 levels in galactosaemic lens epithelial cells are partially reversed by myo-inositol. Acta Diabetologica, 1998, 35, 145-149.	1.2	3
72	Improved fluorometric enzymatic sorbitol assay in human blood. Clinica Chimica Acta, 1998, 273, 171-184.	0.5	23
73	An Inhibitor of Aldose Reductase and Sorbitol Accumulation fromAnthocepharus chinensis. Planta Medica, 1998, 64, 68-69.	0.7	18

#	Article	IF	Citations
74	Identification and Characterization of a Novel Human Aldose Reductase-like Gene. Journal of Biological Chemistry, 1998, 273, 11429-11435.	1.6	259
76	Cyclic AMP regulates expression of the gene coding for a mouse vas deferens protein related to the aldo-keto reductase superfamily in human and murine adrenocortical cells. Journal of Endocrinology, 1999, 160, 147-154.	1.2	40
77	Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia, 1999, 42, 1187-1194.	2.9	67
78	Inhibitory effect of orally administered aldose reductase inhibitor SNK-860 on corneal polyol accumulation in galactose-fed rats. Graefe's Archive for Clinical and Experimental Ophthalmology, 1999, 237, 758-762.	1.0	7
79	Structural and Kinetic Determinants of Aldehyde Reduction by Aldose Reductaseâ€. Biochemistry, 1999, 38, 42-54.	1.2	173
80	Characterization of Genomic Regions Directing the Cell-Specific Expression of the Mouse Aldose Reductase Gene. Biochemical and Biophysical Research Communications, 1999, 255, 759-764.	1.0	9
81	Evaluation of Î± 1 â€adrenoceptor antagonist on diabetesâ€induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB Journal, 2000, 14, 1548-1558.	0.2	44
82	Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily. , 2000, 38, 41-48.		13
83	Aldose and aldehyde reductases: Correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site. Proteins: Structure, Function and Bioinformatics, 2000, 41, 407-414.	1.5	25
84	Crystallization and aldoâ€“keto reductase activity of Gcy1p fromSaccharomyces cerevisiae. Acta Crystallographica Section D: Biological Crystallography, 2000, 56, 763-765.	2.5	14
85	Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products. Free Radical Biology and Medicine, 2000, 29, 17-25.	1.3	53
86	Luteinizing Hormone Induces Mouse Vas Deferens Protein Expression in the Murine Ovary. Endocrinology, 2000, 141, 2574-2581.	1.4	28
87	Aldose Reductase-Deficient Mice Develop Nephrogenic Diabetes Insipidus. Molecular and Cellular Biology, 2000, 20, 5840-5846.	1.1	98
88	Cadmium-Dependent Enzyme Activity Alteration Is Not Imputable to Lipid Peroxidation. Archives of Biochemistry and Biophysics, 2000, 383, 288-295.	1.4	54
89	Aldose Reductase does Catalyse the Reduction of Glyceraldehyde Through a Stoichiometric Oxidation of NADPH. Experimental Eye Research, 2000, 71, 515-521.	1.2	31
90	A Potent Aldose Reductase Inhibitor, (2S,4S)-6-Fluoro-2â€˜,5â€˜-dioxospiro[chroman-4,4â€˜-imidazolidine]-2-carboxamide (Fidarestat):â€‰ Its Absolute Configuration and Interactions with the Aldose Reductase by X-ray Crystallography. Journal of Medicinal Chemistry, 2000, 43, 2479-2483.	2.9	67
91	Effects of dietary galactose and fructose on rats fed diets marginal or adequate in copper for 9â€“21 months. Nutrition Research, 2001, 21, 1078-1087.	1.3	8
92	The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats. Life Sciences, 2001, 68, 1439-1448.	2.0	12

#	Article	IF	Citations
93	Aldose Reductase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2001, 16, 465-473.	0.5	39
94	Stereospecific Interaction of a Novel Spirosuccinimide Type Aldose Reductase Inhibitor, AS-3201, with Aldose Reductase. Biochemistry, 2001, 40, 8216-8226.	1.2	45
95	Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anti-Cancer Drugs, 2001, 12, 129-132.	0.7	66
96	Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabetic Medicine, 2001, 18, 906-914.	1.2	45
97	The role of taurine in diabetes and the development of diabetic complications. Diabetes/Metabolism Research and Reviews, 2001, 17, 330-346.	1.7	238
98	Physiological functions and hormonal regulation of mouse vas deferens protein (AKR1B7) in steroidogenic tissues. Chemico-Biological Interactions, 2001, 130-132, 903-917.	1.7	43
99	Functional genomic studies of aldoâ€“keto reductases. Chemico-Biological Interactions, 2001, 130-132, 673-683.	1.7	31
100	EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radical Biology and Medicine, 2001, 31, 205-216.	1.3	82
101	Comparisons of genomic structures and chromosomal locations of the mouse aldose reductase and aldose reductase-like genes. FEBS Journal, 2001, 259, 726-730.	0.2	11
102	SF-1 (Steroidogenic Factor-1), C/EBPÎ² (CCAAT/Enhancer Binding Protein), and Ubiquitous Transcription Factors NF1 (Nuclear Factor 1) and Sp1 (Selective Promoter Factor 1) Are Required for Regulation of the Mouse Aldose Reductase-Like Gene (AKR1B7) Expression in Adrenocortical Cells. Molecular Endocrinology, 2001, 15, 93-111.	3.7	40
103	Substrate-Induced Up-Regulation of Aldose Reductase by Methylglyoxal, a Reactive Oxoaldehyde Elevated in Diabetes. Molecular Pharmacology, 2002, 61, 1184-1191.	1.0	67
104	Nitric Oxide Prevents Aldose Reductase Activation and Sorbitol Accumulation During Diabetes. Diabetes, 2002, 51, 3095-3101.	0.3	69
105	Neuropathology and pathogenesis of diabetic autonomic neuropathy. International Review of Neurobiology, 2002, 50, 257-292.	0.9	82
106	Aldose reductase activation is a key component of myocardial response to ischemia. FASEB Journal, 2002, 16, 1-22.	0.2	86
107	The Effects of a Traditional Medicine, Fang-ji-huang-qi-tang (Boi-ogi-to), on Urinary Sugar and Sugar Alcohols in Streptozotocin-induced Diabetic Mice.. Journal of Health Science, 2002, 48, 168-172.	0.9	2
108	A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action:Â 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol. Journal of Medicinal Chemistry, 2002, 45, 4398-4401.	2.9	19
109	Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochemical and Biophysical Research Communications, 2002, 299, 183-188.	1.0	56
110	Diabetic vascular dysfunction: Links to glucose-induced reductive stress and VEGF. Microscopy Research and Technique, 2002, 57, 390-407.	1.2	56

#	Article	IF	Citations
111	Structure of human aldose reductase holoenzyme in complex with Statil: An approach to structure-based inhibitor design of the enzyme. Proteins: Structure, Function and Bioinformatics, 2002, 50, 230-238.	1.5	25
112	Structural Biology of the Aldo-Keto Reductase Family of Enzymes: Catalysis and Cofactor Binding. Cell Biochemistry and Biophysics, 2003, 38, 79-101.	0.9	59
113	A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:Â 6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one. Journal of Medicinal Chemistry, 2003, 46, 2283-2286.	2.9	61
114	Aldoâ€“keto reductases as modulators of stress response. Chemico-Biological Interactions, 2003, 143-144, 325-332.	1.7	21
115	Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. Journal of Neurochemistry, 2003, 87, 497-507.	2.1	66
116	Differential expression of the liver proteome in senescence accelerated mice. Proteomics, 2003, 3, 1883-1894.	1.3	73
117	Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress. Journal of the American Society of Nephrology: JASN, 2003, 14, S233-S236.	3.0	467
118	Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy. Medical Hypotheses, 2003, 60, 550-551.	0.8	22
119	Biochemical Pathways for Microvascular Complications of Diabetes Mellitus. Annals of Pharmacotherapy, 2003, 37, 1858-1866.	0.9	59
120	Possible Involvement of Facilitated Polyol Pathway in Augmentation of Intimal Hyperplasia in Rabbits with Alloxan-induced Hyperglycemia. Journal of Cardiovascular Pharmacology, 2003, 41, 265-275.	0.8	6
121	Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications. Current Medicinal Chemistry, 2003, 10, 1389-1398.	1.2	84
122	Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3010-3019.	1.8	64
123	Effects of Polyol Pathway Hyperactivity on Protein Kinase C Activity, Nociceptive Peptide Expression, and Neuronal Structure in Dorsal Root Ganglia in Diabetic Mice. Diabetes, 2004, 53, 3239-3247.	0.3	60
124	Interaction between the Polyol Pathway and Non-Enzymatic Glycation on Mesangial Cell Gene Expression. Nephron Experimental Nephrology, 2004, 98, e89-e99.	2.4	21
125	Central role for aldose reductase pathway in myocardial ischemic injury. FASEB Journal, 2004, 18, 1192-1199.	0.2	124
126	Corneal Changes After Small-Incision Cataract Surgery in Patients WithDiabetes Mellitus. JAMA Ophthalmology, 2004, 122, 966.	2.6	93
127	Aldose Reductase Gene Polymorphisms and Peripheral Nerve Function in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 2021-2026.	4.3	36
128	Pharmacological prevention of diabetic cataract. Journal of Diabetes and Its Complications, 2004, 18, 129-140.	1.2	167

#	Article	IF	Citations
129	Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors. Proteins: Structure, Function and Bioinformatics, 2004, 55, 805-813.	1.5	83
130	Potential role for the sorbitol pathway in the meiotic dysfunction exhibited by oocytes from diabetic mice. The Journal of Experimental Zoology, 2004, 301A, 439-448.	1.4	12
131	Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry. Bioorganic and Medicinal Chemistry, 2004, 12, 3797-3806.	1.4	19
132	Diabetic Retinopathy in Children and Adolescents with Type 1 Diabetes. , 2005, 10, 314-328.		1
133	Aldose Reductase and AGE-RAGE Pathways: Key Players in Myocardial Ischemic Injury. Annals of the New York Academy of Sciences, 2005, 1043, 702-709.	1.8	61
134	Angiotensin-Converting Enzymes: Properties and Function. , 2005, , 95-99.		0
135	Fibrates inhibit aldose reductase activity in the forward and reverse reactions. Biochemical Pharmacology, 2005, 70, 1653-1663.	2.0	24
136	Phorbol ester up-regulates aldose reductase expression in A549 cells: a potential role for aldose reductase in cell cycle modulation. Cellular and Molecular Life Sciences, 2005, 62, 1146-1155.	2.4	15
137	Aldose Reductase in Diabetic Microvascular Complications. Current Drug Targets, 2005, 6, 475-486.	1.0	128
138	Effects of adenosine and adenosine A2Areceptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy. Neurological Research, 2005, 27, 60-66.	0.6	28
139	Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process. Brain, 2005, 128, 1026-1037.	3.7	44
140	Ocular Metabolism and Disposition of 4-Hydroxy-2-nonenal. Cutaneous and Ocular Toxicology, 2005, 24, 165-176.	0.5	1
141	Effect of Diabecon on sugar-induced lens opacity in organ culture: mechanism of action. Journal of Ethnopharmacology, 2005, 97, 397-403.	2.0	32
142	Involvement of nuclear factor Îº B in up-regulation of aldose reductase gene expression by 12-O-tetradecanoylphorbol-13-acetate in HeLa cells. International Journal of Biochemistry and Cell Biology, 2005, 37, 2297-2309.	1.2	12
143	Factorizing Selectivity Determinants of Inhibitor Binding toward Aldose and Aldehyde Reductases:Â Structural and Thermodynamic Properties of the Aldose Reductase Mutant Leu300Proâˆ'Fidarestat Complex. Journal of Medicinal Chemistry, 2005, 48, 5659-5665.	2.9	54
144	A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:â€‰ 6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners. Journal of Medicinal Chemistry, 2005, 48, 6326-6339.	2.9	56
145	Phenolic Marine Natural Products as Aldose Reductase InhibitorsÂ§. Journal of Natural Products, 2006, 69, 1485-1487.	1.5	85
146	The role of polyol pathway in high glucose-induced endothelial cell damages. Diabetes Research and Clinical Practice, 2006, 73, 227-234.	1.1	53

#	Article	IF	Citations
147	On-bead combinatorial techniques for the identification of selective aldose reductase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 7728-7735.	1.4	12
148	Quantitative structureâ€“activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 512-520.	1.0	24
149	Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from Origanum vulgare L. ssp. hirtum. Bioorganic and Medicinal Chemistry, 2006, 14, 1653-1659.	1.4	33
150	Study of the polyol pathway in the porcine epididymis. Molecular Reproduction and Development, 2006, 73, 859-865.	1.0	20
151	Exploring Structural Requirements for Aldose-Reductase Inhibition by 2,4-Dioxo-5-(naphth-2-ylmethylene)-3-thiazolidinyl Acetic Acids and 2-Thioxo Analogues: Fujita-Ban and Hansch Approach. Archiv Der Pharmazie, 2006, 339, 327-331.	2.1	6
152	Analysis of glucose metabolism in diabetic rat retinas. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E1057-E1067.	1.8	84
153	Regulation of Intracellular Glucose and Polyol Pathway by Thiamine and Benfotiamine in Vascular Cells Cultured in High Glucose. Journal of Biological Chemistry, 2006, 281, 9307-9313.	1.6	124
154	Towards Newer Molecular Targets for Chronic Diabetic Complications. Current Vascular Pharmacology, 2006, 4, 45-57.	0.8	52
155	WY 14,643 inhibits human aldose reductase activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2006, 21, 569-573.	2.5	12
156	Cellular Signaling and Potential New Treatment Targets in Diabetic Retinopathy. Experimental Diabetes Research, 2007, 2007, 1-12.	3.8	74
157	Signal Transduction Therapy of Diabetic Vascular Complication. Current Signal Transduction Therapy, 2007, 2, 91-100.	0.3	5
158	Focus on Molecules: Aldose reductase. Experimental Eye Research, 2007, 85, 739-740.	1.2	48
159	En Route to an Efficient Catalytic Asymmetric Synthesis of AS-3201. Journal of the American Chemical Society, 2007, 129, 11342-11343.	6.6	120
160	Diabetic Retinopathy: From Pathogenesis to Treatment. Experimental Diabetes Research, 2007, 2007, 1-2.	3.8	10
161	The atomic resolution structure of human aldose reductase reveals that rearrangement of a bound ligand allows the opening of the safety-belt loop. Acta Crystallographica Section D: Biological Crystallography, 2007, 63, 665-672.	2.5	13
162	Functional studies of aldo-keto reductases in Saccharomyces cerevisiae. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 321-329.	1.9	60
163	Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cellular and Molecular Life Sciences, 2007, 64, 1970-1978.	2.4	56
164	QSAR study of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. Medicinal Chemistry Research, 2008, 17, 258-266.	1.1	8

#	Article	IF	Citations
165	Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovascular Diabetology, 2008, 7, 33.	2.7	43
166	Inhibition of aldose reductase from cataracted eye lenses by finger millet (Eleusine coracana) polyphenols. Bioorganic and Medicinal Chemistry, 2008, 16, 10085-10090.	1.4	111
167	Disruption of aldo-keto reductase genes leads to elevated markers of oxidative stress and inositol auxotrophy in Saccharomyces cerevisiae. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 237-245.	1.9	32
168	Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy. Experimental Eye Research, 2008, 86, 647-652.	1.2	22
169	Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. Physical Therapy, 2008, 88, 1322-1335.	1.1	727
170	Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications. Expert Opinion on Investigational Drugs, 2008, 17, 575-581.	1.9	27
171	Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview. Current Medicinal Chemistry, 2009, 16, 2345-2354.	1.2	62
172	Artificial neural networksâ€based approach to design ARIs using QSAR for diabetes mellitus. Journal of Computational Chemistry, 2009, 30, 2494-2508.	1.5	24
173	Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives. European Journal of Medicinal Chemistry, 2009, 44, 2673-2678.	2.6	73
174	Synthesis and Blood Glucose Lowering Activity of Novel Benzenesulfonyl-Urea Derivatives. Phosphorus, Sulfur and Silicon and the Related Elements, 2009, 184, 2516-2524.	0.8	3
175	Aldo-Keto Reductases in the Eye. Journal of Ophthalmology, 2010, 2010, 1-6.	0.6	22
176	Acetic Acid Derivatives of 3,4-Dihydro-2<i>H</i>-1,2,4-benzothiadiazine 1,1-Dioxide as a Novel Class of Potent Aldose Reductase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 8330-8344.	2.9	55
177	Polyol pathway and diabetic nephropathy revisited: Early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase. Journal of Diabetes Investigation, 2011, 2, 111-122.	1.1	29
178	Identification, cloning and regulation of cDNA encoding Aldoâ€“Keto Reductase 1B7 in the adrenal gland of two saharan rodents Meriones libycus (Libyan jird) and Gerbillus gerbillus (gerbil). General and Comparative Endocrinology, 2011, 174, 292-300.	0.8	0
179	Aldose reductase-mediated induction of epithelium-to-mesenchymal transition (EMT) in lens. Chemico-Biological Interactions, 2011, 191, 351-356.	1.7	35
180	1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase. Bioorganic and Medicinal Chemistry, 2011, 19, 7262-7269.	1.4	43
181	Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold. European Journal of Medicinal Chemistry, 2011, 46, 1536-1544.	2.6	28
182	Inhibitory activities of the edible brown alga Laminaria japonica on glucose-mediated protein damage and rat lens aldose reductase. Fisheries Science, 2011, 77, 1069-1079.	0.7	12

#	Article	IF	Citations
183	The Role of Cys-298 in Aldose Reductase Function. Journal of Biological Chemistry, 2011, 286, 6336-6344.	1.6	20
184	Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications. Current Medicinal Chemistry, 2012, 19, 3578-3604.	1.2	119
185	Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovascular Research, 2012, 94, 370-378.	1.8	53
186	Synthesis and blood glucose lowering activity of some novel benzenesulfonylurea derivatives substituted with 6-aryl-4,5-dihyropyridazin-3(2H)-ones. Medicinal Chemistry Research, 2012, 21, 4352-4356.	1.1	0
187	Osmotic stress induced oxidative damage: Possible mechanism of cataract formation in diabetes. Journal of Diabetes and Its Complications, 2012, 26, 275-279.	1.2	59
188	The polyol pathway in the bovine oviduct. Molecular Reproduction and Development, 2012, 79, 603-612.	1.0	6
189	Practical Catalytic Asymmetric Synthesis of a Promising Drug Candidate. , 2012, , 219-228.		0
190	An Efficient Synthesis of Quinoxalinone Derivatives as Potent Inhibitors of Aldose Reductase. ChemMedChem, 2012, 7, 823-835.	1.6	68
191	Synthesis and blood glucose lowering activity of some novel benzenesulfonylthiourea derivatives substituted with 6-aryl-4,5-dihyropyridazin-3(2H)-ones. Medicinal Chemistry Research, 2012, 21, 428-436.	1.1	3
192	Discovery of New Selective Human Aldose Reductase Inhibitors through Virtual Screening Multiple Binding Pocket Conformations. Journal of Chemical Information and Modeling, 2013, 53, 2409-2422.	2.5	52
193	Aquaporin 5 knockout mouse lens develops hyperglycemic cataract. Biochemical and Biophysical Research Communications, 2013, 441, 333-338.	1.0	36
194	Antioxidant Potential of Fungal Metabolite Nigerloxin during Eye Lens Abnormalities in Galactose-Fed Rats. Current Eye Research, 2013, 38, 1064-1071.	0.7	7
195	The Boar Reproductive System. , 2013, , 65-107.		5
196	Aldoâ€keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy. Australasian journal of optometry, The, 2013, 96, 303-309.	0.6	1
197	Stop Crying over Spilled Milk, Thanks to Recent Reports Which Suggest Novel Therapeutic Options for Existing Aldose reductase Inhibitors. Journal of Biomolecular Research & Therapeutics, 2013, 01, .	0.2	0
198	Aldose Reductase: A Multi-disease Target. Current Enzyme Inhibition, 2013, 10, 2-12.	0.3	14
199	Porcine sperm capacitation involves tyrosine phosphorylation and activation of aldose reductase. Reproduction, 2014, 148, 389-401.	1.1	26
200	Association of Diabetic Autonomic Neuropathy with Red Blood Cell Aldose Reductase Activity. Canadian Journal of Diabetes, 2014, 38, 22-25.	0.4	6

#	Article	IF	Citations
201	Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews, 2014, 30, 669-678.	1.7	67
202	Selective synthesis and comparative activity of olefinic isomers of 1,2-benzothiazine-1,1-dioxide carboxylates as aldose reductase inhibitors. RSC Advances, 2014, 4, 21134.	1.7	10
203	Vicenin 2 isolated from Artemisia capillaris exhibited potent anti-glycation properties. Food and Chemical Toxicology, 2014, 69, 55-62.	1.8	82
204	Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection. European Journal of Medicinal Chemistry, 2014, 76, 352-359.	2.6	28
205	Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs). European Journal of Medicinal Chemistry, 2014, 71, 53-66.	2.6	58
206	Autonomic neuropathy in experimental models of diabetes mellitus. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 579-602.	1.0	16
207	Interaction of aldose reductase and superoxide dismutase activity in liver; influence of vasopressin hormone and its modulators. International Journal of Biomedical Research, 2015, 6, 769.	0.1	0
208	Diabetes and Alzheimer Disease, Two Overlapping Pathologies with the Same Background: Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-14.	1.9	91
209	The inhibitory effect of Isoflavones isolated from Caesalpinia pulcherrima on aldose reductase in STZ induced diabetic rats. Chemico-Biological Interactions, 2015, 237, 18-24.	1.7	20
210	Kinetic and molecular docking studies of loganin and 7-O-galloyl-d-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase. Archives of Pharmacal Research, 2015, 38, 1090-1098.	2.7	15
211	Chiral resolution, determination of absolute configuration, and biological evaluation of (1,2-benzothiazin-4-yl)acetic acid enantiomers as aldose reductase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 846-851.	2.5	7
212	Concomitant and discrete expressions of aldose reductase and sorbitol dehydrogenase in the male reproductive tract. Acta Histochemica, 2016, 118, 776-783.	0.9	5
213	In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol. Biomedicine and Pharmacotherapy, 2016, 84, 502-513.	2.5	33
214	Design and synthesis of chiral 2 H -chromene- N -imidazolo-amino acid conjugates as aldose reductase inhibitors. European Journal of Medicinal Chemistry, 2016, 124, 750-762.	2.6	26
215	Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer & Metabolism, 2016, 4, 11.	2.4	177
216	Characterization of WY 14,643 and its Complex with Aldose Reductase. Scientific Reports, 2016, 6, 34394.	1.6	3
217	Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1). Expert Opinion on Therapeutic Patents, 2016, 26, 731-735.	2.4	2
218	Impact of Diabetic Complications on Balance and Falls: Contribution of the Vestibular System. Physical Therapy, 2016, 96, 400-409.	1.1	69

#	Article	IF	Citations
219	Synthesis and structureâ€"activity relationship studies of phenolic hydroxyl derivatives based on quinoxalinone as aldose reductase inhibitors with antioxidant activity. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 887-892.	1.0	20
220	Strategic Incorporation of Fluorine for Drug Discovery and Development. , 2017, , 499-531.		1
221	Antidiabetic and allied biochemical roles of new chromeno-pyrano pyrimidine compounds: synthesis, in vitro and in silico analysis. Medicinal Chemistry Research, 2017, 26, 805-818.	1.1	19
222	Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2324-2330.	1.0	14
223	Phenolic compounds inhibit the aldose reductase enzyme from the sheep kidney. Journal of Biochemical and Molecular Toxicology, 2017, 31, e21936.	1.4	75
224	Influence of aldose reductase on epithelial-to-mesenchymal transition signaling in lens epithelial cells. Chemico-Biological Interactions, 2017, 276, 149-154.	1.7	16
225	Exploration of thioxothiazolidinoneâ€"sulfonate conjugates as a new class of aldehyde/aldose reductase inhibitors: A synthetic and computational investigation. Bioorganic Chemistry, 2017, 75, 1-15.	2.0	18
226	Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 34-41.	0.6	10
228	Inhibition of Î±-glucosidase, Î±-amylase, and aldose reductase by potato polyphenolic compounds. PLoS ONE, 2018, 13, e0191025.	1.1	162
229	The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacologica Sinica, 2019, 40, 86-97.	2.8	46
230	Flavonoids from Brazilian Cerrado: Biosynthesis, Chemical and Biological Profile. Molecules, 2019, 24, 2891.	1.7	10
231	Exploring antidiabetic potential of adamantyl-thiosemicarbazones via aldose reductase (ALR2) inhibition. Bioorganic Chemistry, 2019, 92, 103244.	2.0	21
232	Polyphenols of marine red macroalga Symphyocladia latiuscula ameliorate diabetic peripheral neuropathy in experimental animals. Heliyon, 2019, 5, e01781.	1.4	12
233	Understanding Aldose Reductase-Inhibitors interactions with free energy simulation. Journal of Molecular Graphics and Modelling, 2019, 91, 10-21.	1.3	10
234	Aldose reductase inhibitors: 2013-present. Expert Opinion on Therapeutic Patents, 2019, 29, 199-213.	2.4	62
235	Synthesis of new arylsulfonylspiroimidazolidine-2Ê¹,4Ê¹-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress. European Journal of Medicinal Chemistry, 2019, 168, 154-175.	2.6	20
236	Identification of quinoxalin-2(1H)-one derivatives as a novel class of multifunctional aldose reductase inhibitors. Future Medicinal Chemistry, 2019, 11, 2989-3004.	1.1	12
237	Structure-Based Drug Design with a Special Emphasis on Herbal Extracts. Challenges and Advances in Computational Chemistry and Physics, 2019, , 271-305.	0.6	0

#	Article	IF	Citations
238	Search for non-acidic ALR2 inhibitors: Evaluation of flavones as targeted agents for the management of diabetic complications. Bioorganic Chemistry, 2020, 96, 103570.	2.0	8
239	Methylglyoxal Metabolism and Aging-Related Disease: Moving from Correlation toward Causation. Trends in Endocrinology and Metabolism, 2020, 31, 81-92.	3.1	71
240	(5-Hydroxy-4-oxo-2-styryl-4H-pyridin-1-yl)-acetic Acid Derivatives as Multifunctional Aldose Reductase Inhibitors. Molecules, 2020, 25, 5135.	1.7	5
241	Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity. Bioorganic and Medicinal Chemistry, 2020, 28, 115699.	1.4	10
242	Screening inhibitory effects of selected flavonoids on human recombinant aldose reductase enzyme: <i>inÂvitro</i> and <i>in silico</i> study. Archives of Physiology and Biochemistry, 2022, 128, 1368-1374.	1.0	9
243	Non-Enzymatic Glycation and Formation of Advanced Glycation End-Products Alters the Activity and Related Kinetic Properties of Aldose Reductase. Asian Journal of Chemistry, 2021, 33, 1875-1880.	0.1	0
244	Evaluation of the Therapeutic Effects of Protocatechuic Aldehyde in Diabetic Nephropathy. Toxins, 2021, 13, 560.	1.5	7
245	Curious effects of fluorine on medicinally active compounds. , 2021, , 241-276.		5
247	Mechanisms of Glucose- and Diabetes-Induced Vascular Dysfunction. , 1992, , 107-132.		14
248	Kinetic Alteration of Human Aldose Reductase by Mutagenesis of Cysteine Residues. Advances in Experimental Medicine and Biology, 1993, 328, 289-300.	0.8	4
249	Polymorphisms of the Aldose Reductase Locus (ALR2) and Susceptibility to Diabetic Microvascular Complications. Advances in Experimental Medicine and Biology, 1993, 328, 325-332.	0.8	21
250	Regulation of Aldose Reductase by Aldehydes and Nitric Oxide. Advances in Experimental Medicine and Biology, 1999, 463, 501-507.	0.8	2
251	A Potential Role for Aldose Reductase in Steroid Metabolism. Advances in Experimental Medicine and Biology, 1996, 414, 465-473.	0.8	13
252	High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia, 1994, 37, 328-330.	2.9	6
253	The Lens. , 2011, , 131-163.		10
254	Aldose reductase from human skeletal and heart muscle. Interconvertible forms related by thiol-disulfide exchange.. Journal of Biological Chemistry, 1990, 265, 20982-20987.	1.6	60
255	Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303.. Journal of Biological Chemistry, 1992, 267, 24833-24840.	1.6	103
256	The crystal structure of the aldose reductase.NADPH binary complex.. Journal of Biological Chemistry, 1992, 267, 24841-24847.	1.6	85

#	Article	IF	Citations
257	Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications.. Journal of Biological Chemistry, 1992, 267, 4364-4369.	1.6	256
258	Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms.. Journal of Biological Chemistry, 1990, 265, 10912-10918.	1.6	59
259	Cloning and expression of human aldose reductase.. Journal of Biological Chemistry, 1990, 265, 9788-9792.	1.6	73
260	Bovine lens aldose reductase. pH-dependence of steady-state kinetic parameters and nucleotide binding.. Journal of Biological Chemistry, 1993, 268, 25494-25499.	1.6	20
261	Probing the active site of human aldose reductase. Site-directed mutagenesis of Asp-43, Tyr-48, Lys-77, and His-110.. Journal of Biological Chemistry, 1993, 268, 25687-25693.	1.6	109
262	Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor.. Journal of Clinical Investigation, 1997, 99, 2192-2202.	3.9	172
263	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.. Journal of Clinical Investigation, 1998, 101, 1905-1915.	3.9	377
264	Structural Studies of Aldose Reductase Inhibition. , 2018, , 229-246.		1
265	Effects of Bogijetong-Tang on Diabetic-peripheral Neuropathy Induced by Streptozotocin in the Mouse. Journal of Korean Medicine, 2013, 34, 126-142.	0.1	3
266	Potential of Gentiana lutea for the Treatment of Obesity-associated Diseases. Current Pharmaceutical Design, 2019, 25, 2071-2076.	0.9	5
267	Polyol pathway: A possible mechanism of diabetes complications in the eye. African Vision and Eye Health, 2015, 74, .	0.1	29
268	Neuroprotective efficacy of polyphenols of marine brown macroalga Ecklonia cava in diabetic peripheral neuropathy. Pharmacognosy Magazine, 2019, 15, 468.	0.3	1
269	Aldose Reductase Inhibitory Activity of Butea monosperma for the Management of Diabetic Complications. Pharmacologia, 2015, 6, 355-359.	0.3	1
275	Diabetic Retinopathy: Its Progression and the Effective Treatment to Prevent Blindness. Pharmacologia, 2013, 4, 138-156.	0.3	0
276	Antidiabetic Drugs. , 1990, , 613-623.		0
277	THE CRYSTAL STRUCTURE OF THE ALDOSE REDUCTASE NADPH BINARY COMPLEX. , 1992, 267, 24841-7.		82
278	Roles of Alkaloids from Medicinal Plants in the Management of Diabetes Mellitus. Journal of Chemistry, 2021, 2021, 1-10.	0.9	23
279	Non-insulin-dependent (type II) diabetes mellitus. Cmaj, 1991, 145, 1571-81.	0.9	3

#	Article	IF	Citations
280	Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. Molecular Vision, 2012, 18, 495-503.	1.1	33
281	Resorcinol Derivatives as Novel Aldose Reductase Inhibitors: In Silico and In Vitro Evaluation. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
282	Rhodanine scaffold: A review of antidiabetic potential and structureâ€"activity relationships (SAR). Medicine in Drug Discovery, 2022, 15, 100131.	2.3	13
284	Algal metabolites: Paving the way towards new generation antidiabetic therapeutics. Algal Research, 2023, 69, 102904.	2.4	4
285	Pantothenate Kinase 4 Governs Lens Epithelial Fibrosis by Negatively Regulating Pyruvate Kinase M2-Related Glycolysis. , 2023, .		0
287	Role of Medicinal Plants in the Management of Diabetes Mellitus. , 2023, , 89-103.		0